TITLE

Antithrombotic treatment for peripheral arterial disease

AUTHOR(S)
Hackam, Daniel G.; Eikelboom, John W.
PUB. DATE
March 2007
SOURCE
Heart;Mar2007, Vol. 93 Issue 3, p303
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context: Patients with peripheral arterial disease (PAD) bear a substantial risk for vascular events in the coronary, cerebral and peripheral circulations. In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis. Objective: To determine the optimal antithrombotic prophylaxis for patients with PAD. Data sources: Using terms related to PAD and antithrombotic agents, we searched the following databases for relevant articles: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, the National Institutes of Health Clinical Trials Database, Web of Science, and the International Pharmaceutical Abstracts Database (search dates: 1 January 1990 to 1 January 2007). Additional articles were identified from cardiovascular and vascular surgery conference proceedings, bibliographies of review articles, and personal files. Study selection: We focused on randomised trials, systematic reviews and consensus guidelines of antithrombotic therapies for PAD. Data extraction: Detailed study information was abstracted by each author working independently. Results: Multiple studies show that patients with PAD manifest platelet hyperaggregability, increased levels of soluble platelet activation markers, enhanced thrombin generation and altered fibrinolytic potential. Many of these markers predict subsequent cardiovascular events. Available randomised trials and meta-analyses show that most available antithrombotic agents prevent major cardiovascular events and death in patients with PAD, including aspirin, aspirin/dipyridamole, clopidogrel, ticlopidine, picotamide and oral anticoagulants. Conclusions: Although the most favourable risk-benefit profile, cost-effectiveness and overall evidence base supports aspirin in this setting, we provide scenarios in which alternatives to aspirin should be considered.
ACCESSION #
24399475

 

Related Articles

  • Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atriai fibrillation. Connofly, S. J.; Pogue, J.; Hart, R.; Sloan, Michael A. // Evidence Based Medicine;Dec2006, Vol. 11 Issue 6, p170 

    The article cites that clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in patients with atrial fibrillation. Limitations of the study include the rates of stroke and other vascular events which were lower than in other trials. Some bias probably...

  • Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. Zimarino, Marco; Renda, Giulia; Raffaele De Caterina // Drugs;2005, Vol. 65 Issue 6, p725 

    Four weeks’ therapy with clopidogrel, in addition to aspirin (acetylsalicylic acid), is currently standard care after percutaneous coronary intervention (PCI) with stent implantation. The recent availability of drug-eluting stents (DES), which dramatically reduce restenosis at the site of...

  • Harvard Clinical Research Institute Successfully Completes Randomization in the DAPT Study.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article provides information on the completion of the randomization in the dual antiplatelet therapy (DAPT) by the Harvard Clinical Research Institute (HCRI). It also informs that DAPT Study is a four-year clinical trial investigating the duration of DAPT which is a combination of aspirin...

  • Oral Anticoagulant + Antiplatelet Therapy = Danger.  // Travel Medicine Advisor;Sep2007, Vol. 17 Issue 9, p1 

    The article discusses a study on the effectiveness of adding an anticoagulant to aspirin in patients with peripheral artery disease (PAD). It notes that antiplatelet drugs are commonly prescribed for such patients. According to the findings, the combination of the drugs can be dangerous. The...

  • Regado's aptamer lines up against anticoagulants. Sinha, Gunjan // Nature Biotechnology;Dec2013, Vol. 31 Issue 12, p1060 

    The article reports on the phase three clinical trials of the drug REG1 Anticoagulant system developed by Regado Biosciences of Basking Ridge, New Jersey.

  • Aspirin + warfarin boosts bleeding.  // Cortlandt Forum;May2008, Vol. 21 Issue 5, p8 

    The article reports on the findings of the clinical trial involving combination therapy patients, conducted by Samuel G. Johnson and colleagues from Kaiser Permanente in the U.S. The investigators conducted an analysis involving 2,560 adults treated with anticoagulant warfarin and 1,623...

  • No significant difference in primary outcome between warfarin or aspirin.  // Australian Journal of Pharmacy;Oct2012, Vol. 93 Issue 1109, p74 

    The article discusses the trial aimed at determining the potential of warfarin or aspirin to treat patients in sinus rhythm, with reduced left ventricular ejection fraction (LVEF). It states that there were no significant differences in the primary outcome between warfarin and aspirin among...

  • Challenges of anticoagulant therapy in patients with atrial fibrillation in clinical practice. Hobbs, Richard // QJM: An International Journal of Medicine;Mar2012, Vol. 105 Issue 3, p295 

    No abstract available.

  • Aspirin + clopidogrel therapy: How does your care compare to the evidence? Simmons, B. Brent; Salzman, Brooke E. // Journal of Family Practice;Jan2008, Vol. 57 Issue 1, p26 

    The article focuses on the latest trials and recommendations on dual antiplatelet therapy as they pertain to acute coronary syndrome (ACS), coronary stents, stroke, and the primary prevention and secondary prevention of distant cardiovascular events. One of the trials cited is The Clopidogrel in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics